

Applications

- Combination therapy using currently marketed drugs
- Cancer treatment

Advantages

- Reduced development of drug resistance
- Increased efficiency of cancer therapy
- New and improved use for already existing drugs

Inventors

[Paul Dent, Ph.D.](#)

Hossein Hamed, Ph.D.

Contact

T. Allen Morris, Ph.D., MBA
Associate Director

amorris5@vcu.edu


Direct 804-827-2211

Market Need

Chemotherapy agents are often combined with each other or other drugs to enhance their therapeutic effects. Combination chemotherapy has been consistently shown to be superior to the use of single agents mostly due to reduced development of drug resistance and improved tumor response to the therapy.

Technology Summary

This technology presents potentially novel combination drug therapy for cancer. Dr. Dent has shown that Sorafanib, a drug approved for primary kidney and liver cancer, interacts with a certain group of inhibitors in a greater than additive fashion to kill tumor cells. It has been shown that this combination enhances the toxicity of the DNA damaging chemotherapeutics agents in tumor cells via activation of the death receptor CD95. Presented figure demonstrates the effect of combination therapy on survival of three different hepatoma cell lines.



The effect of combination therapy on survival of three different hepatoma cell lines.

Technology Status

In vitro data available.

Patent pending: U.S. and foreign right available

This technology is available for licensing to industry for further development and commercialization.